Abstract:Objective:To evaluate the clinical value of technetium-99m labelled small molecule against prostate speciifc membrane antigen (PSMA) (HYNIC-Glu-Urea-A, 99mTc-PSMA) in the detection of primary and metastatic prostate cancers. Methods:A total of 69 consecutive prostate cancer patients who received 99mTc-PSMA SPECT/CT were retrospectively analyzed. The sensitivity of 99mTc-PSMA for the detection of the primary and metastatic lesions was evaluated. The relationships between positive 99mTc-PSMA and prostate speciifc antigen (PSA) level and Gleason score were analyzed. Results:Of all patients, 6 cases with PSA<0.2 ng/mL after radical prostatectomy remained biochemically disease-free. Based on per patient, in 77.8%(49/63) of the patients at least one lesion indicative of prostate cancer was detected by 99mTc-PSMA SPECT/CT. The level of PSA in the patients with positive 99mTc-PSMA imaging was signiifcantly higher than that in the patients with negative 99mTc-PSMA imaging (PSA median 25.52 ng/mL, range:0.85-3 239 ng/mL) vs. (PSA median 0.35 ng/mL, range:0.003-9.28 ng/mL)(P<0.001). Among newly diagnosed patients and recurrent patients with PSA>1.0 ng/mL, 99mTc-PSMA imaging was able to detect lesions with improved sensitivity of 97.4%(37/38);furthermore, among recurrent patients with PSA>10.0 ng/mL, the number and extent of lesions detected by 99mTc-PSMA SPECT/CT increased signiifcantly. Gleason score in the patients with positive 99mTc-PSMA imaging was signiifcantly higher than that in the patients with negative 99mTc-PSMA imaging (P<0.001). Conclusion:Among newly diagnosed prostate cancer patients and recurrent patients with PSA>1.0 ng/mL, 99mTc-PSMA SPECT/CT can detect prostate cancer and metastases in a high number of patients and can provide important information for clinical treatment decision.

Clinical value of 99mTc-PSMA SPECT/CT in detection of prostate cancer